LWM
ABBV icon

Lionshead Wealth Management’s AbbVie ABBV Stock Holding History

Lionshead Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
4,720
+2,322
+97% +$500K 0.77% 38
2026
Q1 		$522K Sell
2,398
-23
-1% -$5.1K 0.38% 58
2025
Q4 		$553K Buy
2,421
+23
+1% +$5.24K 0.42% 57
2025
Q3 		$555K Buy
2,398
+756
+46% +$154K 0.44% 56
2025
Q2 		$305K Buy
1,642
+8
+0.5% +$1.49K 0.28% 71
2025
Q1 		$342K Sell
1,634
-1,525
-48% -$296K 0.36% 63
2024
Q4 		$561K Buy
+3,159
New +$581K 0.41% 51

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Lionshead Wealth Management's ABBV Position: Q2 2026 in Review

Lionshead Wealth Management increased its AbbVie (ABBV) stake by 97% in Q2 2026, buying an estimated $500K and bringing the position to 4,720 shares worth $1.19M. The position accounts for 0.77% of the portfolio, ranked #38.

Lionshead Wealth Management first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Lionshead Wealth Management held 4,720 shares of AbbVie worth $1.19M as of Q2 2026.
  • Lionshead Wealth Management bought 2,322 AbbVie shares in Q2 2026, an estimated $500K.
  • AbbVie made up 0.77% of Lionshead Wealth Management's portfolio in Q2 2026, its #38 holding.
  • Lionshead Wealth Management first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lionshead Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.